RxDoctor Payments Data

Tony Kannarkat, MD

Family Medicine · Silver Spring, MDNPI 1073543237

Payments from drug & device makers

$890in general payments, 2019–2025

Across 31 payments — averaging $28.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$443
  • Esperion Therapeutics, Inc.$125
  • Boehringer Ingelheim$122
  • Novo Nordisk$67
  • Lilly USA, LLC$50
  • GSK$35
  • plus $47 from 2 others

What the payments were for

  • Food & beverage$890100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca10$443
Esperion Therapeutics, Inc.1$125
Boehringer Ingelheim8$122
Novo Nordisk4$67
Lilly USA, LLC3$50
GSK2$35
AbbVie(2 entities)2$34
Merck1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$890 in reported general payments places this provider in the 65th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$37,924
Medicare patients
91
Services billed
292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin11$6,616
Tresiba Flextouch U-100Insulin Degludec11$5,681
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro14$3,015
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid25$2,537
Rosuvastatin Calcium52$854
Nano 2nd Gen Pen NeedlePen Needle, Diabetic12$798
Atorvastatin Calcium72$793
Tamsulosin Hcl31$521
Amlodipine Besylate60$473
Albuterol Sulfate HfaAlbuterol Sulfate21$417
Metoprolol Succinate33$414
Metformin Hcl ErMetformin Hcl61$379
Losartan Potassium29$342
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide30$333
Glimepiride32$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$122$6,61611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →